
via The Scientist RSS https://ift.tt/TbzfF4u The Biogen-developed treatment, called lecanemab, appears to have a more clear-cut effect on slowing the disease than the company’s previous Alzheimer’s drug, Aduhelm. https://ift.tt/vfZJNs3 September 29, 2022 at 02:38AM
Comments
Post a Comment